Skip to content
Back to search

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1a zur subkutanen Injektion (ATC-Code nach WHO: L03AB07)

AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPublished on Mar 04, 2026
601 days left

Description

The subject of this publication is the conclusion of non-exclusive discount agreements under Section 130a, paragraph 8, SGB V for medicines with the active substance Interferon beta-1a for subcutaneous injection (ATC code according to WHO: L03AB07). The contract will be concluded within the framework of an "Open-House" model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations will not be conducted and there will be no (supply) exclusivity. It is noted that the purchase quantity is unknown, as it depends on demand and the development of the number of insured persons, the prescribing behaviour of doctors, and the dispensing and stocking behaviour of public pharmacies. Minimum purchase quantities are therefore not guaranteed. Interested pharmaceutical companies can download the participation documents from the project room of the German Tender Portal (DTVP). To do so, an application for access to the project room is required. Once the applicant has been granted access by the contracting authority, the participation documents can be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents, in particular regarding the content of the discount agreement and the rebates mentioned therein. Any full or partial disclosure or disclosure of contents of the participation documents to or for third parties requires the prior written consent of the contracting authority. If participation is waived, all documents must be destroyed immediately in a data-protection-compliant manner. The documents to be submitted are detailed in the documents "Cover Letter" and "Explanation of Contract Terms" deposited in the project room. Communication, including the transmission of the participation documents, will be conducted electronically via the tender portal DTVP; further details can be found in the aforementioned documents. Any contrary information in the contract notice is due to technical reasons and is not binding. Participation applications can be submitted for the first time by 2 April 2026. All further submission deadlines can be found in the annex "Submission Deadlines" deposited in the project room. If the deadline for submission falls on a Saturday, Sunday or a public holiday nationwide, the next working day will take its place. In the event of late receipt, the submitted participation applications will be considered for the next submission deadline. The discount agreement will end, regardless of the date of contract conclusion, no later than 30 April 2028. The contracting authority reserves the right to terminate the open-house procedure prematurely, in particular in the event of the conclusion of exclusive discount agreements; in this case, the discount agreements already concluded will end in accordance with the contractual provisions. According to the experience of the contracting authority, exclusive discount agreements usually come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders